On March 13, 2019 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, reported that it has received approximately $3.0 million in proceeds from holders exercising common stock purchase warrants at an exercise price of $6.60 per share (Press release, Trovagene, MAR 13, 2019, View Source [SID1234534289]). The warrants were issued as part of the units sold in the Company’s public offering which closed on June 12, 2018.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Trovagene is a clinical-stage oncology therapeutics company, using a precision medicine predictive biomarker approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers. Onvansertib, its lead drug candidate, is a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor. The Company currently has two ongoing open-label clinical trials: a Phase 1b/2 trial in acute myeloid leukemia (AML) and a Phase 2 trial in metastatic castration-resistant prostate cancer (mCRPC).
"We are pleased with recent activities as more investors are becoming aware of our multi-faceted clinical development program of Onvansertib, a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor," said Thomas Adams, Chief Executive Officer and Chairman of Trovagene. "Our program currently includes three open-label trials – Acute Myeloid Leukemia, metastatic Castration Resistant Prostate Cancer and metastatic Colorectal Cancer – all of which are indications where there is a significant need to bring new treatment options to patients."